Eledon Pharmaceuticals, Inc. (ELDN) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
011M22M34M45M56M68M79M90MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0815223038455260Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
04M8M11M15M19M22M26M30MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-30M-26M-22M-19M-15M-11M-7M-4M1Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

EPSEPS Diluted
000111222Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
0612192531384450Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-40-35-30-25-20-14-9-41Q4 2024

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-20-17-15-12-10-7-4-21Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Breakdown

Operating IncomeTotal Other Income Expenses NetNet Income
038M75M112M150M188M225M262M300MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000111222Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueStock Based Compensation To Revenue
01020304050607080Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
04M8M11M15M19M22M26M30MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
012M25M38M50M62M75M88M100MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics